Results 171 to 180 of about 1,946 (264)

Optimization of pharmaceutical research and development by early‐phase assessment of investigational medicinal products

British Journal of Clinical Pharmacology, EarlyView.
Small and mid‐sized pharmaceutical innovators often have limited in‐house health economics and market access expertise, and may struggle to align development strategies of investigational medicinal products with health system needs and payer expectations.
Zoltán Kaló, Attila Imre, Gábor Varga, Sándor Kovács, György Tímár, Balázs Nagy   +5 more
wiley   +1 more source

Species Diversity of Mosquitoes (Diptera: Culicidae) in Various Coastal Bioecological Regions of Southern Iran. [PDF]

J Trop Med
Abbasi E, Alipour H, Azari-Hamidian S, Azizi K, Darabi A, Amiri S, Bakhshi H, Darvishi M, Moemenbellah-Fard MD.   +8 more
europepmc   +1 more source

Cost–benefit analysis of screening programme for diabetic retinopathy in Bulgaria

British Journal of Clinical Pharmacology, EarlyView.
Aims Late‐diagnosed diabetic retinopathy (DR) is difficult and expensive to treat. Screening programmes can identify the disease early and reduce the costs of its future treatment. This study aims to analyse the cost–benefit of screening programmes for DR.
Iva Nenkova, Yoana Lilova, Alexander Oscar, Alina Levi, Maria Kamusheva, Guenka Petrova   +5 more
wiley   +1 more source

Unravelling phenotypic variations and establishing a core collection in mungbean for accelerating the crop improvement programs. [PDF]

Front Plant Sci
Kalia RK, Gayacharan, Patil DK, Wankhede DP, Aravind J, Singh N, Kumar P, Singh AK, Panchariya P, Choudhary M, Solanki K, Kakani RK, Rani R, Mahla HR, Gomashe S, Latha M, Shekhawat N, Pathak R, Singh K, Singh GP.   +19 more
europepmc   +1 more source

Cost‐utility analysis of nusinersen–risdiplam switch in patients with spinal muscular atrophy in Croatia: A discrete event simulation model

British Journal of Clinical Pharmacology, EarlyView.
Introduction In recent years, the treatment of spinal muscular atrophy (SMA), a rare disease, has significantly progressed, improving patients' survival and overall quality of life. However, current SMA treatments are expensive, and some (nusinersen) are very inconvenient for patients.
Andrej Belančić, Ivana Stević, Elvira Meni Maria Gkrinia, Dinko Vitezić, Slobodan Janković   +4 more
wiley   +1 more source

Reasoning and empathy are not competing but complementary features of altruism. [PDF]

PNAS Nexus
Law KF, Syropoulos S, Amormino P, Marsh A, Young L, O'Connor BB.   +5 more
europepmc   +1 more source

How the HTAR will contribute to a value‐based decision‐making for medicinal products across the EU

British Journal of Clinical Pharmacology, EarlyView.
The European Union Health Technology Regulation 2021/2282 (HTAR) introduces joint assessment of health technologies (including medicinal products and medical devices) across EU Member States. It was signed into law in 2021 and came into full force in January 2025.
Roisin Adams, Michal Stanak
wiley   +1 more source

Optimizing Interventions for Equitability: Some Initial Ideas. [PDF]

Prev Sci
Strayhorn JC, Vanness DJ, Collins LM.
europepmc   +1 more source

Beyond the label: Rethinking off‐label drug use in paediatrics. Towards a scientifically grounded and safer future for paediatric pharmacotherapy

British Journal of Clinical Pharmacology, EarlyView.
Abstract Despite regulatory progress being made in the past two decades, off‐label drug use in paediatrics remains pervasive, with prevalence estimated between 3% and 97% of prescriptions across different clinical settings. Off‐label use—defined as prescribing outside the conditions described in the Summary of Product Characteristics (SmPC)—is often ...
Tjitske M. van der Zanden, Miriam G. Mooij, Matthijs de Hoog, Saskia N. de Wildt   +3 more
wiley   +1 more source

Machine Learning and Geospatial Modeling of Climate Change Impacts on Ethiopian Honeybees for Conservation and Resilient Agriculture. [PDF]

Ecol Evol
Tulu D, Yasin KH, Gelete TB, Ahmed B, Belina D.   +4 more
europepmc   +1 more source